A-TAP - Arthritis Therapy Acceleration Programme
The Arthritis Therapy Acceleration Programme (A-TAP) is an exciting new £7M concept funded by the Kennedy Trust for Rheumatology Research. It brings together the Universities of Birmingham and Oxford and seven NHS partners and is supported by our access to over 7million patients. The initiative is aiming to support and develop novel treatments for arthritis based on the underlying causes of inflammatory disease.
This ambition is facilitated by our innovative new approach to translational inflammation research through our application of unique rigorous signal seeking experimental medicine studies leading to rapid adoption into clinical trials underpinned by novel trial design. The results will help us treat the cause of disease not just their symptoms and help develop a new taxonomy of disease that moves away from a traditional “organ-based, speciality-focussed” approach to a process-driven, pathway-focussed classification for inflammatory diseases.
Latest news from the Kennedy Institute
3 September 2019
Researchers at the Kennedy Institute identify a molecular pathway to boost vaccine responses in the elderly.
21 August 2019
Oxford is the newest partner of the national Research into Inflammatory Arthritis Centre Versus Arthritis (RACE) which has been awarded continued funding of nearly £2m over the next five years from Versus Arthritis.
21 August 2019
Find out more about what our work experience students thought about their experience at NDORMS by watching the video below.
2 July 2019
The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of £20M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.